Deal demonstrates Medtronic's commitment to expanding pipeline through strategic investments and targeted acquisitions

交易展示了美敦力通过战略投资和有针对性的收购来扩大其产品线的决心。

Exercising option to acquire will bolster Medtronic's interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated

行使收购期权将增强美敦力的介入心脏病学产品组合，扩大其在改变心血管疾病诊断和治疗方式方面的领导地位。

Medtronic's intent to acquire follows a 2022 strategic partnership agreement with CathWorks

美敦力意图收购紧随其与CathWorks达成的2022年战略合作伙伴协议。

GALWAY,

戈尔韦，

Ireland

爱尔兰

,

，

Feb. 3, 2026

2026年2月3日

/

/

PRNewswire

美通社

/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System in the U.S., .

/ -- 全球医疗技术领导者美敦力公司（Medtronic plc，纽约证券交易所代码：MDT）今天宣布将行使选择权收购私营医疗器械公司CathWorks。CathWorks致力于变革冠状动脉疾病（CAD）的诊断和治疗方法。此次收购意向是继2022年双方达成战略合作伙伴关系之后的进一步举措，当时签署了在美国共同推广CathWorks FFRangio®系统的协议。

Europe

欧洲

and

和

Japan

日本

, where it is commercially available. The acquisition is valued at up to

，它已经在市场上销售。此次收购价值高达

$585 million

5.85亿美元

with potential undisclosed earn-out payments post-acquisition.

潜在的未披露的收购后盈利支付。

'Medtronic is thrilled to move forward with our option to officially acquire CathWorks. Through our co-promotion agreement, we've seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient's journey, from diagnosis to treatment,' said .

“美敦力很高兴能够行使我们的选择权，正式收购CathWorks。通过我们的联合推广协议，我们已经看到CathWorks如何颠覆传统的基于导线的FFR细分市场，并利用数据和人工智能的力量提供创新解决方案，在患者旅程的每一步为医生提供帮助，从诊断到治疗，”美敦力表示。

Jason Weidman

杰森·魏德曼

, senior vice president and president of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic. 'This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care.' .

，冠状动脉及肾去神经业务的高级副总裁兼总裁，该业务隶属于美敦力的心血管产品组合。 “此次收购使美敦力能够通过提供实时数据、指导个体化治疗方案并推动新护理标准的技术，来变革导管实验室。”

Evaluating the physiological significance of coronary artery stenosis is essential to improving patient outcomes. Coronary physiology, most commonly assessed using fractional flow reserve (FFR), helps physicians identify which lesions truly cause ischemia. This enables appropriate revascularization for patients who need it, while avoiding unnecessary percutaneous coronary intervention (PCI) in those who do not.

评估冠状动脉狭窄的生理学意义对于改善患者预后至关重要。冠状动脉生理学通常通过使用分数流储备（FFR）来评估，这有助于医生识别哪些病变确实导致了缺血。这使得需要接受血运重建的患者能够得到适当治疗，同时避免对不需要的患者进行不必要的经皮冠状动脉介入治疗（PCI）。

FFR is an important diagnostic tool with strong clinical evidence that demonstrates its improved clinical outcomes and economic benefits..

FFR 是一个重要的诊断工具，具有强有力的临床证据，证明了其改善临床结果和经济效益的能力。

1, 2

1, 2

Despite its proven benefits, traditional wire-based FFR remains underutilized. This is largely due to its invasive nature, which requires the use of pressure wires, pharmacologic hyperemia, and measurements limited to a single transducer location within the vessel.

尽管传统基于导线的FFR已被证明有诸多益处，但其使用仍然不足。这主要是因为它的侵入性特点，需要使用压力导丝、药物诱导的充血状态，并且测量仅限于血管内的单一传感器位置。

Alternatively, using a combination of artificial intelligence (AI) and advanced computational science, the CathWorks FFRangio System provides a comprehensive physiological assessment of the entire coronary tree directly from routine coronary angiograms (X-rays). Robust clinical evidence has demonstrated excellent diagnostic accuracy and promising clinical outcomes when compared with wire-based FFR..

此外，CathWorks FFRangio 系统结合人工智能 (AI) 和先进的计算科学，直接从常规冠状动脉造影（X 光）中提供对整个冠状动脉树的全面生理评估。强有力的临床证据表明，与基于导丝的 FFR 相比，该系统具有出色的诊断准确性和良好的临床结果。

3,4

3,4

'We are thrilled to have CathWorks officially become part of the Medtronic family,' said

“我们很高兴CathWorks正式成为美敦力家族的一部分，”

Ramin Mousavi

拉明·穆萨维

, president and chief executive officer of CathWorks. 'Our successful co-promotion over the past three years has unlocked significant opportunities in the coronary physiology market through the expanded utilization of our innovative technology. With Medtronic's vast global footprint, FFRangio will continue to reach even more patients globally.

CathWorks的总裁兼首席执行官表示：“在过去的三年中，我们成功的共同推广已经在冠状动脉生理学市场中释放了巨大的机会，这得益于我们创新技术的广泛应用。凭借美敦力广泛的全球影响力，FFRangio将继续惠及全球更多患者。”

Bringing Medtronic and CathWorks together will create a best-in-class organization focused on driving new standards of care to transform the cath lab.'  .

将美敦力和CathWorks结合在一起，将创建一个一流的组织，专注于推动新的护理标准以变革导管实验室。

This deal is pending clearance from the United States Federal Trade Commission (FTC). This phase is expected to be completed by the end of Medtronic's fiscal year 2026, subject to applicable regulatory approvals and other customary closing conditions. At the date of the acquisition closing, CathWorks will then become a part of Medtronic.

该交易有待美国联邦贸易委员会 (FTC) 的批准。此阶段预计将在美敦力 2026 财年年底前完成，但须符合相关监管机构的批准及其他惯例成交条件。在收购完成之日，CathWorks 将成为美敦力的一部分。

Medtronic and CathWorks will continue to operate independently until the deal is closed..

美敦力和CathWorks将继续独立运营，直到交易完成。

Financial Highlights

财务亮点

This acquisition is expected to be immaterial to Medtronic's fiscal year 2027 GAAP and adjusted earnings per share and neutral to accretive thereafter.

此次收购预计对美敦力2027财年的GAAP和调整后每股收益影响不大，此后将保持中性或增值。

About FFRangio

关于FFRangio

Using a combination of artificial intelligence (AI) and advanced computational science, the CathWorks FFRangio® System is the only angiography-derived system that delivers FFR values along the entire coronary tree. In addition, it provides intraprocedural optimization tools, including assessment of the physiological impact of lesion treatment and interactive sizing tools to measure lesion dimensions.

结合人工智能 (AI) 和先进的计算科学，CathWorks FFRangio® 系统是唯一一个能够沿整个冠状动脉树提供FFR值的血管造影衍生系统。此外，它还提供了术中优化工具，包括评估病变治疗的生理影响以及用于测量病变尺寸的交互式尺寸调整工具。

Together, these capabilities empower physicians with deeper physiological insights to support confident, patient-centered treatment decisions.*.

这些能力相结合，赋予医生更深入的生理学洞察力，以支持自信、以患者为中心的治疗决策。*

About CathWorks

关于CathWorks

CathWorks, based in Kfar Saba, Israel, is the leader in coronary digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated.

CathWorks总部位于以色列卡法萨巴，是冠状动脉数字健康创新的领导者，其创新技术可以改善全球患者的生活。CathWorks FFRangio® 系统结合了人工智能和先进的计算科学，彻底改变了心血管疾病的诊断和治疗方法。

The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFR values for the entire coronary tree. For more information on CathWorks, visit .

FFRangio系统从常规血管造影中获取生理信息，无需药物刺激和侵入性压力导丝。它为医生提供整个冠状动脉树的快速可靠的术中FFR值。有关CathWorks的更多信息，请访问。

www.cath.works

www.cath.works

and follow

跟随

@CathWorks

@CathWorks

on

打开

Twitter

Twitter

and

和

LinkedIn

领英

.

。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway,

大胆思考。更大胆的行动。我们是美敦力。美敦力公司，总部位于戈尔韦，

Ireland

爱尔兰

, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

是全球领先的医疗技术公司，勇敢地应对人类面临的最棘手的健康问题，通过寻找并发现解决方案。我们的使命——减轻痛苦、恢复健康、延长生命——将遍布150多个国家的95,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和治疗手段涵盖70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多样化的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多精彩，因为我们致力于推动以洞察力为导向的护理、以人为本的体验，以及为我们的世界创造更好的成果。在我们所做的每一件事中，我们都在创造非凡。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow Medtronic on

并关注美敦力

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力公司向证券交易委员会提交的定期报告中描述的风险和不确定性。实际结果可能与预期结果有重大差异。

*

*

The results of CathWorks FFRangio

CathWorks FFRangio 的结果

®

®

are intended to be used by qualified clinicians in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional evaluation.

旨在由合格的临床医生结合患者的临床病史、症状、其他诊断测试以及临床医生的专业评估来使用。

1.

1.

Bernard De Bruyne

伯纳德·德布鲁因

, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Bindu Kalesan, M.P.H.,

，医学博士，哲学博士，尼科·H·J·皮尔斯，医学博士，哲学博士，宾杜·卡莱桑，公共卫生硕士，

Emanuele Barbato

埃马努埃莱·巴尔巴托

, M.D., Ph.D.,

，医学博士，哲学博士，

Pim A.L. Tonino

皮姆·A·L·托尼诺

, M.D., Ph.D.,

，医学博士，哲学博士，

Zsolt Piroth

佐尔特·皮罗什

, M.D.,

，医学博士，

Nikola Jagic

尼古拉·贾吉奇

, M.D., Sven Möbius-Winkler, M.D., Gilles Rioufol, M.D., Ph.D.,

，医学博士，斯文·默比乌斯-温克勒，医学博士，吉尔斯·里奥福尔，医学博士，哲学博士，

Nils Witt

尼尔斯·维特

, M.D., Ph.D.,

，医学博士，哲学博士，

Petr Kala

彼得·卡拉

, M.D.,

，医学博士，

Philip MacCarthy

菲利普·麦卡锡

, M.D., Thomas Engström, M.D.,

，医学博士，托马斯·恩斯特罗姆，医学博士，

Keith G. Oldroyd

基思·G·奥尔德罗伊德

, M.D., Kreton Mavromatis, M.D., Ganesh Manoharan, M.D.,

，医学博士，克雷顿·马夫罗马蒂斯，医学博士，甘尼什·马诺哈兰，医学博士，

Peter Verlee

彼得·维尔利

, M.D., Ole Frobert, M.D., Nick Curzen, B.M., Ph.D.,

医学博士，奥勒·弗罗伯特，医学博士，尼克·库尔岑，医学学士，哲学博士，

Jane B. Johnson

简·B·约翰逊

, R.N., B.S.N., Peter Jüni, M.D., and

，注册护士，理学士，彼得·尤尼，医学博士，和

William F. Fearon

威廉·F·费尔森

, M.D., for the FAME 2 Trial Investigators. Fractional Flow Reserve–Guided PCI versus Medical Therapy in stable coronary disease.

医学博士，FAME 2 试验研究者。分数流储备指导下的PCI与药物治疗在稳定型冠心病中的对比。

The New England Journal of Medicine

新英格兰医学杂志

2012; 367:991-1001DOI: 10.1056/NEJMoa1205361

2012; 367:991-1001 DOI: 10.1056/NEJMoa1205361

2. Fearon et al. Economic Evaluation of Fractional Flow Reserve-guided Percutaneous Coronary Intervention in Patients with Multivessel Disease. Circulation. 2010;122:2545-2550.

2. Fearon 等。多支血管病变患者中血流储备分数引导的经皮冠状动脉介入治疗的经济评估。《循环》。2010；122：2545-2550。

3. Witberg G, De Bruyne B, Fearon WF, Achenbach S, Engstrom T, Matsuo H, et al. Diagnostic performance of angiogram-derived fractional flow reserve: a pooled analysis of 5 prospective cohort studies.

3. Witberg G, De Bruyne B, Fearon WF, Achenbach S, Engstrom T, Matsuo H, 等。血管造影衍生的分数流储备的诊断性能：5项前瞻性队列研究的汇总分析。

JACC Cardiovasc Interv.

JACC心血管介入分册。

(2020) 13:488–97. 10.1016/j.jcin.2019.10.045

(2020) 13:488–97. 10.1016/j.jcin.2019.10.045

4. Tanigaki T, et al. Provision Trial. Data presented at PCR 2025;

4. 谷垣 T 等。供应试验。数据在PCR 2025上发布；

Paris, France

法国巴黎

Contacts:

联系人：

Krystin Hayward

克莉丝汀·海沃德

Public Relations

公共关系

+1-508-261-6512

+1-508-261-6512

Ingrid Goldberg

英格丽德·戈德堡

Investor Relations

投资者关系

+1-763-505-2696

+1-763-505-2696

SOURCE Medtronic plc

来源：美敦力公司